Navigation Links
Researchers test old drug with new hopes for pre-eclampsia cure
Date:9/14/2007

GALVESTON, Texas Researchers at the University of Texas Medical Branch at Galveston are trying to determine whether a drug already available to heart patients can also be used to delay delivery in expectant mothers with severe preeclampsia. If so, this groundbreaking study would give hope to hundreds of thousands of women who experience this life-threatening disorder each year.

The drug, Digibind, has been prescribed for over 20 years to patients who overdose on a certain heart medication, but is not yet approved for preeclampsia, the most common and dangerous pregnancy complication affecting as many as eight in every 100 pregnant women. The disorder is characterized by high blood pressure, protein in the urine and multi-organ dysfunction, all of which can seriously harm both mother and fetus.

Preeclampsia is the No. 1 killer of pregnant women in the world, and there is no cure except delivery, said Dr. George Saade, chief of maternalfetal medicine at UTMB. When it is severe and occurs early in the pregnancy, delivery in order to protect the mother results in a premature baby. Thats why this study is important, because if the medication works, then we can protect the mom while allowing the baby to grow and develop without delivering early.

The clinical trial will test whether Digibind reverses or prevents the abnormalities that occur with preeclampsia and allows the fetus to remain in the womb longer. This would give doctors more time to administer steroids to prevent respiratory complications in premature births and reduce the need for costly and lengthy neonatal intensive care.

Right now, there is no treatment for preeclampsia, so this is truly groundbreaking, said Dr. Nicole Ruddock, the studys principal investigator and an instructor in UTMBs Department of Obstetrics and Gynecology.


'/>"/>

Contact: Kristen Hensley
k.hensley@utmb.edu
409-772-8772
University of Texas Medical Branch at Galveston
Source:Eurekalert

Page: 1

Related medicine news :

1. Researchers urge caution in using ear tube surgery
2. Researchers Scale to assess the Severity of Epilepsy in Kids
3. Researchers identify the early makers of Neonatal Sepsis
4. OHSU Researchers Announce New Discovery
5. Researchers Identify Gene Connected To Bipolar Disorder
6. Ecstasy shrinks brain!!-researchers unveil the secrets of MDMA.
7. Researchers trick Alzheimers Enzyme
8. Researchers find new HIV hiding place
9. Gene researchers make Malaria-resistant mosquito
10. New Hair in 15 Days Could Now Be A Possibility Say Researchers
11. Researchers developed world’s smallest toothbrus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...holders to be held on January 8, 2009 , , T... International Inc. ("MedEmerg") (OTCBB: MDER), on..., announced today that it has obtained an interim ...oncerning its previously announced plan of arrange...lth Group Inc. ("AIM") will acquire all of MedEmer...
(Date:11/21/2008)...he University of Texas Health Science Center at Ho...ce in Aging Studies (TEXAS), to promote geriatrics...million award from the Donald W. Reynolds Foundati...ll allow us to teach geriatric medicine principles...to practicing physicians. With the reach of Lyndon...
(Date:11/21/2008)... Heska Corporation,(Nas...he New York Society of,Security Analysts, 12th An...ecember 2, 2008 at 1177 Avenue of the Americas, 2n...duled to begin at 9:35 a.m. Eastern Time (7:35 a.m...ebcast and for two weeks,following the presentati...
(Date:11/21/2008)... The Generic,Pharmaceut...tement today from,GPhA President and CEO Kathleen...TC) roundtable on "Emerging Health Care Competitio...at the FTC is conducting this roundtable demonstra...sumers have access to safe and,affordable biogene...
Breaking Medicine News(10 mins):Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 2Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4Health News:GPhA Statement on FTC Roundtable on Biogenerics 2
...A new study suggests that children with hemophilia...ses joint pain and swelling, are more at risk // ... their later years. But there is hope in preventi...dren, say researchers. Hemophiliac children are no...
...Eighty percent of the time childhood acute lymphob...bad news is doctors are not sure // why it doesn’...new research finds it could be because of a small ...rugs used to treat the disease. Researchers teste...
...A new study finds MRIs are significantly better at...ping cancers than standard mammograms // or clinic...omen with a lifetime breast cancer risk of 15 perc...so carried one of the genes known to put women at ...
...Moms-to-be have one more good reason not to smoke....ing during the early months // of pregnancy increa...e study, involved women from Scotland and England ...ere about six months old. Researchers asked about ...
Other Medicine News:
(Date:11/20/2008)... WASHINGTON, Nov. 20 T...h & Gender Equity: , , WHAT: World AI... , Tuesday, November 25, 2008 , 11:00 a.m. E...trongly encouraged: https://cc.readytalk.com/r/1x...ions outpacing the number of people newly put on t...
(Date:11/20/2008)... , , , , PHILADELPHIA, Nov. 20 /P...K ) today announced that the United States Food an...proval for PROMACTA(R) (eltrombopag) for the treat...immune (idiopathic) thrombocytopenic purpura (ITP)...teroids, immunoglobulins or splenectomy. The appro...
(Date:11/20/2008)... REINACH, Switzerland, November 20 /PRNewswir...y that the Anti-infective Drugs Advisory Committee...as voted 17 to 2 against the,approval of intraven...nt for,the treatment of patients with complicated...luding those caused by methicillin-resistant Staph...
(Date:11/20/2008)... EMERYVILLE, Calif., Nov. 20 /PRNewswire-FirstCal...he company will present results from the Phase 1B,...dvanced metastatic breast,cancer, BZL101, at the ...onal,Conference in Atlanta, Georgia. The Company...g abstract and will be presented as a part of the ...
Breaking Medicine Technology:Faith and Civil Society Leaders Call for Truth and Leadership in U.S. HIV Prevention Efforts 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 3Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5Minnesota Reaches Milestone in Goal to End Homelessness 28155 1Minnesota Reaches Milestone in Goal to End Homelessness 28155 2NovoLogix Launches First Annual Symposium for Healthcare Thought Leaders 28151 1NovoLogix Launches First Annual Symposium for Healthcare Thought Leaders 28151 2NovoLogix Launches First Annual Symposium for Healthcare Thought Leaders 28151 3Men are better at detecting infidelities 5647 1Men are better at detecting infidelities 5647 2Women at Higher Risk for Pulmonary Hypertension 28144 1Women at Higher Risk for Pulmonary Hypertension 28144 2
...FORT LEE, N.J.--(BUSINESS WIRE)--Jun 21, 2007 - Ne...blication in the June 23 issue,of the journal The ...e therapy trial for Parkinson,s disease and the fi...s own brain cells for any adult,neurodegenerative ...in 12 patients with,advanced Parkinson,s disease d...
..."Electroloading of mature dendritic cells with tum...ponse", GAITHERSBURG, Md., and YOKOHAMA, Japan, Ju...net Co., Ltd. announce a,joint poster presentation...ociety for Cellular Therapy. The meeting is being,...presentation is entitled "Electroloading of mature...
Other Medicine Technology:Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 2Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 3Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 4Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 5Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 6MaxCyte and Medinet to Present at the 13th Annual Meeting of the,International Society for Cellular Therapy (ISCT) in Sydney,Australia 2MaxCyte and Medinet to Present at the 13th Annual Meeting of the,International Society for Cellular Therapy (ISCT) in Sydney,Australia 3
This is adapted to microplate or card.
ScanGel® Incubator
The ID-Micro Typing System™ (ID-MTS) Gel Test is suitable for a broad range of blood bank applications. Applications that include antibody screening and identification, ABO blood grouping and R
...Mini-Vertical Gel System simplifies the process of...AGE format. It is able to run four gels at a time,...tility and throughput, the 120 mini-vertical runs ...120 mini-vertical has a modular design. The basic ...
Medicine Products: